Cite
HARVARD Citation
Wen, P. et al. (2022). Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet oncology. 23 (1), pp. 53-64. [Online].